Clinical Trial Detail

NCT ID NCT02238496
Title Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Andrew Lassman
Indications

glioblastoma multiforme

astrocytoma

oligodendroglioma

malignant glioma

gliosarcoma

mixed glioma

Therapies

Perifosine + Temsirolimus

Age Groups: adult

No variant requirements are available.